Dogwood Therapeutics Inc. Publishes Investor Presentation Highlighting Progress in Halneuron® Phase 2b Study for Chemotherapy-Induced Neuropathic Pain and New SP16 Cancer Pain License
Dogwood Therapeutics Inc. (NASDAQ: DWTX) has updated its research on chemotherapy-induced peripheral neuropathy (CINP) and cancer pain. The company is advancing its Phase 2b study of Halneuron®, a Nav1.7 inhibitor, focusing on pain intensity changes over four weeks. Additionally, Dogwood announced a royalty-free license for Serpin Pharma’s SP16, aimed at treating chemotherapy-related neuropathy. The Phase 1b trial of SP16 is funded by the National Cancer Institute, with an IND application expected in Q4 2025 and patient dosing in H1 2026.
Dogwood Therapeutics Inc. (NASDAQ: DWTX) recently provided an update on its research and development activities targeting chemotherapy-induced peripheral neuropathy (CINP) and cancer-related pain. The company highlighted progress in its ongoing Phase 2b clinical study of Halneuron®, a Nav1.7 inhibitor, for the treatment of moderate-to-severe CINP. The study is exploring both the safety and efficacy of Halneuron®, with the primary endpoint focused on changes in patient-reported pain intensity over four weeks, as measured by daily e-diary entries. Secondary endpoints include assessments of fatigue, sleep quality, pain interference, and mood symptoms. Dogwood Therapeutics also announced a global, royalty-free license agreement for Serpin Pharma’s intravenous SP16, which is being developed to address neuropathy and nerve damage associated with chemotherapy. Preclinical studies report that SP16 demonstrates anti-inflammatory and analgesic properties through reduction of key inflammatory markers. The Phase 1b trial of SP16 is being conducted in collaboration with the University of Virginia and is fully funded by the National Cancer Institute. Plans are in place to file an Investigational New Drug (IND) application for SP16 in the fourth quarter of 2025, with patient dosing anticipated in the first half of 2026. You can access the full presentation through the link below. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dogwood Therapeutics Inc. published the original content used to generate this news brief on September 29, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
